Viridian Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Viridian Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 94% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 3,898% in 3 years, but profit fell: $308 less profit per $100 of extra sales. Lower than 92% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-363.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 94% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 0/3Sales grew in 1 of the last 3 years; profit grew in 0 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
−$308Sales grew 3,898% in 3 years, but profit fell: $308 less profit per $100 of extra sales.
Lower than 92% of Healthcare companies in United States.
Asset Productivity Ratio
+3898% / +107%In 3 years sales changed by +3898% while total assets changed by +107%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-367.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 96% of Healthcare companies in United States.
Cash Cushion Ratio
+32%Cash, after subtracting all debt, equals 32% of its market value (net cash).
Higher than 69% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Viridian Therapeutics, Inc. made a loss over the last year. Viridian Therapeutics, Inc. owes $0.40 for every $1 it owns. Viridian Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossViridian Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.83The share price is 3.83 times Viridian Therapeutics, Inc.'s book value per share, higher than 64% of Healthcare companies in United States.
Market cap
$2.5 BThe total market value of all of Viridian Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 79% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$662 MWhat Viridian Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$5.84Net worth divided by the number of shares. The share price of $22.37 is 3.8 times this, which is the P/B above.
Return on equity (ROE)
-65.7%Viridian Therapeutics, Inc. lost 65.7% of its shareholders' money over the last year, lower than 60% of Healthcare companies in United States.
Owes vs Owns
0.40×Viridian Therapeutics, Inc. owes $0.40 for every $1 it owns (low), lower than 52% of Healthcare companies in United States.
Dividend yield
NoneViridian Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+23360%Revenue rose 23360% in the year to Dec 2025, and grew 242% a year on average over 3 years.
Profit growth
LossViridian Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-483.6%Viridian Therapeutics, Inc. lost $484 for every $100 of revenue.
Interest cover
Not coveredViridian Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashViridian Therapeutics, Inc. held $824 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Viridian Therapeutics, Inc.: $2.5 B ÷ $662 M (30 Jun 2026) = 3.8.
What is Viridian Therapeutics, Inc.'s return on equity?
Viridian Therapeutics, Inc. lost 65.7% of its shareholders' money over the last year, lower than 60% of Healthcare companies in United States.
How much does Viridian Therapeutics, Inc. owe compared with what it owns?
Viridian Therapeutics, Inc. owes $0.40 for every $1 it owns (low), lower than 52% of Healthcare companies in United States.
Does Viridian Therapeutics, Inc. pay a dividend?
No. Viridian Therapeutics, Inc. does not currently pay a dividend.
Is Viridian Therapeutics, Inc.'s revenue growing?
Revenue rose 23360% in the year to Dec 2025, and grew 242% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.